Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company based in Rockville, MD. They are pioneers in the development of vaccines using their proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which harnesses the body's natural biochemistry to generate broad immune responses. With a primary focus on oncology, ITI has built a pipeline of programs in oncology, animal health, infectious disease, and allergy, utilizing the UNITE platform.
ITI's investigational UNITE platform leverages engineered chimeric proteins to direct antigen presenting cells to present antigens to the immune system through a targeted pathway, resulting in a robust immune response. Their pipeline includes ITI-1000, a dendritic cell therapy for glioblastoma multiforme (GBM), ITI-1001, an off-the-shelf cancer immunotherapy for GBM, and ITI-3000, a plasmid DNA vaccine for Merkel cell carcinoma. Through their innovative approach, ITI aims to transform lives by pioneering vaccines that have the potential to revolutionize immunotherapy for cancer, allergies, and animal health.
Generated from the website